Apremilast in the Treatment of Uveitis

Oregon Health & Science University (OHSU)

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Uveitis

Treatments: Drug: Apremilast

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00889421

e4235

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with vision-threatening autoimmune uveitis
• failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects

Exclusion criteria

• serious concomitant illness that could interfere with the subject's participation
• previous or current use of an alkylating agent
• use of CYP3A4 inhibitors during the trial
• TNF blocker use within the 8 weeks prior to enrollment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

Treatment

Experimental group

Description:

Patients receiving apremilast.

Treatment:

Drug: Apremilast